This site is intended for healthcare professionals only
LoginRegister
Alembic Pharmas Karakhadi Injectable Facility USFDA Inspection6 step-down subsidiaries of Alembic Pharma dissolves
NGT seeks response from Environment Ministry on Hyderabad pharma unit blastNGT seeks response from Environment Ministry on Hyderabad pharma unit blast
Biocon Biologics Gets Health Canada Nod for Yesintek, a Biosimilar to StelaraBiocon gets EIR with VAI status from USFDA for Bengaluru API facility
Novartis AG to Exit India Arm in Rs 1,446 Cr Deal, ChrysCapital-Led Consortium Buys 70.68% StakeUS Appeals Court decision favors MSN Pharma in Novartis heart drug Entresto generic dispute
Revise Phase III Trial Protocol for Roflumilast Cream: CDSCO Panel Tells Sun PharmaConduct phase III clinical study on resistant hypertension: CDSCO Panel tells Sun Pharmaceutical...
Zydus Gets USFDA Approval for Generic Evoxac (Cevimeline) CapsulesZydus Lifscience gets CDSCO Panel nod to study Rabies Vaccine
CDSCO Expert Panel Backs Akums Faropenem Dispersible Tablets, Grants CT, BE WaiversAkum Drugs & Pharmaceutical gets CDSCO Panel nod for BE study of FDC Eplerenone plus Torsemide...
Jubilant Generics invests Rs 20 lakh in Jubilant Pharma CanadaLaurus Bio secures equity infusion of Rs 120 crore
Shilpa Medicare ink pact to sell 31 percent stake in Sravathi Advanced Process Technologies for Rs 49.6 croreTeva to divest Teva-Takeda, its Business Venture in Japan
Emcure to Market Roches CellCept, Mircera, Neorecormon Under New India PactGilead Sciences, Tubulis ink pact to develop ADC candidate for select solid tumor target
Pfizer, TevaPfizer Gets CDSCO Panel Nod To Import 20 Valent Pneumococcal Conjugate Vaccine
Novartis declares positive results from phase III study for new malaria treatmentInclisiran be sold by retail under prescription of cardiologist only: CDSCO panel tells Novartis...
X